The
Antibody Partnering Terms and Agreements report provides comprehensive
understanding and unprecedented access to the antibody partnering deals and
agreements entered into by the worlds leading healthcare companies.
The
report provides a detailed understanding and analysis of how and why companies
enter antibody partnering deals. The majority of deals are discovery or
development stage whereby the licensee obtains a right or an option right to
license the licensors antibody technology. These deals tend to be
multicomponent, starting with collaborative R&D, and commercialization of
outcomes.
This report provides details
of the latest antibody agreements announced in the healthcare sectors,
covering:
- Antibodies
- Antibody-drug conjugates
- Monoclonal antibodies
- Murine mAb
- Chimeric mAb
- Humanized mAb
- Human aAb
- Polyclonal Antibodies
Understanding
the flexibility of a prospective partner’s negotiated deals terms provides
critical insight into the negotiation process in terms of what you can expect
to achieve during the negotiation of terms. Whilst many smaller companies will
be seeking details of the payments clauses, the devil is in the detail in terms
of how payments are triggered – contract documents provide this insight where
press releases do not.
This
report contains over 900 links to online copies of actual antibody deals and
contract documents as submitted to the Securities Exchange Commission by
companies and their partners. Contract documents provide the answers to
numerous questions about a prospective partner’s flexibility on a wide range of
important issues, many of which will have a significant impact on each party’s
ability to derive value from the deal.
The
initial chapters of this report provide an orientation of antibody dealmaking
and business activities.
Chapter 1 provides an introduction to the report,
whilst chapter 2 provides an
overview of the trends in antibody dealmaking since 2009, including details of
average headline, upfront, milestone and royalty terms.
Chapter 3
provides a review of the leading antibody deals since 2009. Deals are listed by
headline value, signed by big pharma, most active big pharma and big biotech,
and most active of all biopharma companies. Where the deal has an agreement
contract published at the SEC a link provides online access to the contract.
Chapter 4
provides a comprehensive listing of the top 50 bigpharma companies with a brief
summary followed by a comprehensive listing of antibody deals, as well as
contract documents available in the public domain. Where available, each deal
title links via Weblink to an online version of the actual contract document,
providing easy access to each contract document on demand.
Chapter 5
provides a comprehensive listing of the top 50 big biotech companies with antibodies
deals announced along with a brief summary followed by a comprehensive listing
of antibody deals, as well as contract documents available in the public
domain. Where available, each deal title links via Weblink to an online version
of the actual contract document, providing easy access to each contract
document on demand.
Chapter 6
provides a comprehensive and detailed review of antibody partnering deals
signed and announced since 2009, where a contract document is available in the
public domain. The chapter is organized by stage of development at signing,
deal type (collaborative R&D, co-promotion, licensing etc), specific
therapy focus and specific technology type. Each deal title links via Weblink
to an online version of the deal record and the contract document, providing
easy access to each contract document on demand.
Chapter 7
provides a comprehensive and detailed review of antibody partnering deals
signed and announced since January 2009. The chapter is organized by specific
antibody technology type in focus. Each deal title links via Weblink to an
online version of the deal record and where available, the contract document,
providing easy access to each contract document on demand.
The
report also includes numerous tables and figures that illustrate the trends and
activities in antibody partnering and dealmaking since 2009.
In
addition, a comprehensive appendix is provided organized by antibody partnering
company A-Z ,deal type, stage of development type and therapy type. Each deal
title links via Weblink to an online version of the deal record and where
available, the contract document, providing easy access to each contract
document on demand.
In
conclusion, this report provides everything a prospective dealmaker needs to
know about partnering in the research, development and commercialization of
antibody technologies and products.
Report scope
Antibody
Partnering Terms and Agreements is intended to provide the reader with an
in-depth understanding and access to antibody trends and structure of deals
entered into by leading companies worldwide.
Antibody Partnering Terms
and Agreements includes:
- Trends in antibody dealmaking in the biopharma industry since 2009
- Analysis of antibody deal structure
- Access to headline, upfront, milestone and royalty data
- Case studies of real-life antibody deals
- Access to over 900 antibody contract documents
- The leading antibody deals by value since 2009
- Most active antibody dealmakers since 2009
- The leading antibody partnering resources
In Antibody Partnering Terms
and Agreements, the available contracts are listed by:
- Company A-Z
- Headline value
- Stage of development at signing
- Deal component type
- Specific therapy target
Each
deal title links via Weblink to an online version of the deal record and where
available, the contract document, providing easy access to each contract
document on demand.
The Antibody Partnering
Terms and Agreements report provides comprehensive access to available deals
and contract documents for over 1,500 antibody deals. Analyzing actual contract
agreements allows assessment of the following:
- What are the precise antibody rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How aresalesand payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
Benefits
Antibody
Partnering Terms and Agreements provides the reader with the following key
benefits:
- In-depth understanding of antibody deal trends since 2009
- Access to headline, upfront, milestone and royalty data
- Analysis of the structure of antibody agreements with numerous real life case studies
- Comprehensive access to over 900 actual antibody deals entered into by the world’s biopharma companies
- Detailed access to actual antibody contracts enter into by the leading companies
- Insight into the terms included in a antibody agreement, together with real world clause examples
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Spanning over 1449 pages, “Antibody Partnering Terms and Agreements” report covering the Trends
in antibody dealmaking, Leading antibody deals, Big pharma antibody deals, Big
Biotech antibody deals, Antibody dealmaking directory with contract documents,
By antibody technology type, Antibody partnering resource center, Appendices.
For more information see - http://mrr.cm/ZMV
Find all Pharma and
Healthcare Reports at:
No comments:
Post a Comment
Note: only a member of this blog may post a comment.